Metabolomic Profiling in Diabetes and Cardiovascular Disease



  • Jubilant Life Sciences

Start Date:

End Date:

  • Completed

Metabolomic Profiling in Diabetes and Cardiovascular Disease

Cardiovascular disease and diabetes are reaching epidemic proportions in the US and in developing countries. India, in particular, has shown marked increases in the rates of these two diseases with major public health impact. The epidemiology and mechanisms underlying these trends are incompletely understood. Novel molecular profiling methods may help us better under these mechanisms, as well as identifying biomarkers useful for risk prediction and targeting of vulnerable populations. For example, we previously identified metabolomic signatures associated with coronary artery disease, incident cardiovascular events, and diabetes. Therefore, we hypothesize that metabolomic profiling in an Indian population will validate previously identified biomarkers for CVD and DM, and will possibly identify novel biomarkers of risk. To test this hypothesis, in collaboration with Jubilant, Jubilant First Trust, and the Rabindranath Tagore International Institute of Cardiac Sciences, we collected clinical data and biological samples in an Indian population referred for cardiac catheterization.